サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：mRNAワクチン市場-世界の産業規模、シェア、動向、機会、予測、2018-2028年
市場調査レポート
商品コード
1321045

mRNAワクチン市場-世界の産業規模、シェア、動向、機会、予測、2018-2028年

mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By mRNA Type, By Application, Region and Competition

出版日
ページ情報
英文 112 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

mRNAワクチン市場-世界の産業規模、シェア、動向、機会、予測、2018-2028年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 112 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

mRNAワクチンの世界市場は、生産、安全性、有効性、流通などの面で、DNAワクチンよりもmRNAワクチンの方が様々な利点があることから、予測期間中に目覚ましい成長を遂げる見通しです。

mRNAワクチンの世界市場は、がん、遺伝子異常、ウイルス感染などの発生率の上昇によって牽引されています。2020年には、死亡者数の約6人に1人にあたる約1,000万人ががんで死亡し、世界的に死因の上位を占める。TAA（腫瘍関連抗原）、TSA（腫瘍特異的抗原）、およびそれらに関連するサイトカインはすべて、mRNAワクチンによってコード化・発現させることができ、がんワクチンの重要なクラスを構成しています。mRNAがんワクチンは体液性免疫と細胞性免疫の両方を高めることができるため、これらのワクチンは様々な疾患や患者に適応しやすいです。その上、COVID-19パンデミックの突然の発生と広がり、COVID-19に対するModernaとPfizer-BioNTechのワクチンの成功は、今後数年のmRNAワクチン市場の成長に新たな展望を生み出すと期待されています。その結果、多くのバイオテクノロジー・製薬企業や学術・研究機関が名乗りを上げ、さまざまな種類のmRNAワクチンの開発に向けて研究開発や臨床試験を開始し、予測期間中の世界のmRNAワクチン市場の成長に有利な機会を生み出しています。clinicaltrials.govによると、mRNAワクチンに関する444件の臨床研究が、世界のさまざまな地域でさまざまな開発段階にあります。

mRNAワクチンの利点

mRNAワクチンの製造は、細胞培養を必要としないため、他のワクチンの製造と比較した場合、利点があります。反応速度が速いため、他の高度なワクチン製造技術に見られるような汚染のリスクは小さいです。さらに、mRNAワクチンは非集積性で細胞内で一過性に発現するため、より安全です。配列が最適化されたmRNAを脂質でカプセル化したものや裸の状態で使用するmRNAワクチンは、特に近年、インフルエンザウイルス、ジカウイルス、狂犬病ウイルスなどの動物モデルにおいて、感染症標的に対する強力な免疫力を生み出しています。

mRNAベースのワクチン製造に向けた研究活動の活発化

より高い生物学的有効性、増強された強力な免疫原性、低毒性レベルでの汎用性の高いデリバリープラットフォームなど、mRNAが他の治療法に比べて提供する数多くの利点が、この分野で現在行われている研究開発の主な推進力となっています。糖尿病、HIV、がん、心血管疾患などの感染症や慢性疾患の予防を目的としたmRNAベースのワクチンの開発は、広範な研究の対象となっています。現在、COVID-19以外の疾患を予防するmRNAワクチンを用いた臨床試験が430件行われています。Clinicaltrials.govの分析によれば、これらの臨床試験の大半は米国で実施されています。

ペンシルバニア大学ペレルマン医学部の研究者たちによって、既知の20種類すべてのインフルエンザウイルス亜型を予防する、多価のmRNAベースのワクチンが作られました。研究者たちは、亜型に共通する抗原を少なくするのではなく、それぞれの亜型に特有の抗原を含めることによって、万能インフルエンザ・ワクチンを作ろうとした以前の試みとは異なるアプローチをとっています。ファイザーとモデナが製造したSARS-CoV-2ワクチンは、この戦略と同じmRNA技術を使用しています。ペンは、これらのCOVID-19ワクチンに使用されているmRNA技術の開発におけるリーダーでした。

市場セグメンテーション

世界のmRNAワクチン市場は、mRNAタイプ別、用途別、地域別に区分することができます。mRNAタイプに基づくと、市場はヌクレオシド修飾mRNA、非修飾mRNA、自己増幅mRNAに分けられます。用途に基づくと、市場はCOVID-19 mRNAワクチン、非COVID-19 mRNAワクチン、その他に分けられます。地域別では、mRNAワクチンは北米、欧州、アジア太平洋、南米、中東・アフリカに分類されます。

市場プレイヤー

Arcturus Therapeutics Holdings Inc.、BioNTech SE、CureVac N.V.、第一三共株式会社、Ethris GmbH、GlaxoSmithKline plc、Gennova Biopharmaceuticals Ltd、Moderna, Inc.、Pantherna Therapeutics GmbH、Providence Therapeutics、Silence Therapeutics、Translate Bio、VERSAMEB AG、Verve Therapeutics Inc.などは、mRNAワクチンの世界市場で事業を展開する大手企業です。

利用可能なカスタマイズ

TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 調査対象年
    • 主要市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主要協会と二次情報源
  • 予測手法
  • データの三角測量と検証
  • 仮定と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレーヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向の概要

第4章 臨床試験分析

  • 進行中の臨床試験
  • 完了した臨床試験
  • 終了した臨床試験
  • パイプラインの開発段階別内訳
  • パイプラインのステータス別内訳
  • パイプラインの内訳、試験タイプ別
  • パイプラインの地域別内訳
  • 臨床試験ヒートマップ

第5章 VOC (顧客の声)

第6章 mRNAワクチンの世界市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • mRNAタイプ別
    • 用途別
    • 地域別
    • 企業別
  • 製品マップ
    • mRNAタイプ別
    • 用途別
    • 地域別

第7章 北米のmRNAワクチン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • mRNAタイプ別
    • 用途別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州のmRNAワクチン市場展望

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • mRNAタイプ別
    • 用途別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域のmRNAワクチン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • mRNAタイプ別
    • 用途別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米のmRNAワクチン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • mRNAタイプ別
    • 用途別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのmRNAワクチン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • mRNAタイプ別
    • 用途別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 最近の動向
  • 合併買収
  • 製品上市

第14章 mRNAワクチンの世界市場：SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Arcturus Therapeutics Holdings Inc.
    • BioNTech SE
    • CureVac N.V.
    • Daiichi Sankyo Company Limited.
    • Ethris GmbH
    • GlaxoSmithKline plc
    • Gennova Biopharmaceuticals Ltd
    • Moderna, Inc.
    • Pantherna Therapeutics GmbH
    • Providence Therapeutics
    • Silence Therapeutics
    • Translate Bio
    • VERSAMEB AG
    • Verve Therapeutics Inc.

第17章 戦略的提言

目次
Product Code: 14521

Global mRNA vaccine market is poised to grow at an impressive rate during the forecast period on account of the various benefits of mRNA vaccine over DNA vaccine in terms of production, safety, efficacy, and distribution, among others. Global mRNA Vaccine Market is driven by the rising incidence of cancer, genetic abnormalities, and viral infections. Approximately 10 million deaths, or nearly one in six deaths, happened due to cancer in 2020, making it one of the top causes of death globally. TAA (tumor-associated antigens), TSA (tumor-specific antigens), and their related cytokines can all be encoded and expressed by mRNA vaccines, which constitute a significant class of cancer vaccines. These vaccines are more adaptable to various diseases and patients because mRNA cancer vaccines can boost both humoral and cellular immunity. Besides, the sudden outbreak and spread of the COVID-19 pandemic and the success of Moderna's and Pfizer- BioNTech's vaccines against COVID-19 are expected to create new prospects for growth of the mRNA vaccine market in the coming years. This has, in turn, resulted in many biotechnology & pharmaceutical companies and academic & research institutions coming forward and starting research and development and launching clinical trials for the development of different types of mRNA vaccines, thereby creating lucrative opportunities for the growth of global mRNA vaccine market during the forecast period. According to clinicaltrials.gov, around 444 clinical studies related to mRNA Vaccines are in different phases of development being conducted across different parts of the globe.

The important reason for encouraging extensive study and deployment of mRNA vaccines is their numerous distinctive benefits. One of the main causes for the development of mRNA vaccines is their convenience of production. Simple in form, its active component, RNA, is often produced in vitro utilizing linear DNA as a template. Through codon optimization, nucleoside modification, and an additional delivery method, the stability and translation efficiency of mRNA can be enhanced during this process to create a nucleic acid vaccine with high specificity and resilient stability. The vaccine's safety is another important aspect that encourages widespread use. There is no potential risk of infection or genetic damage because the mRNA does not integrate into the host genome.

mRNA vaccines create proteins that cause human bodies to generate an immune response. Since these vaccines don't involve live viruses, there is absolutely no risk of getting sick after receiving them. The body quickly breaks down mRNA, and cells don't readily take up foreign mRNA. Recent technological advancements have improved the stability of the mRNA molecule and wrapped the molecules in lipids to improve cell delivery effectiveness. These developments boost the production of spike protein in your cells, triggering a stronger immunological response.

Furthermore, owing to recent technological developments in enhanced translation, stability, and delivery methods, messenger RNAs have emerged as a promising therapeutic tool. In fact, mRNA vaccines have opened the door to new pharmacological fields and have become a significant therapeutic class. The development of vaccines is entering a new age because of these mRNA vaccines, which support next-generation vaccinations.

Industry expansion is anticipated to be supported during the projected time by increased investments in the development of cutting-edge and efficient mRNA vaccines. For instance, American mRNA therapeutic developer Arcturus Therapeutics established a Japanese company in Chiba Prefecture in April 2021 as part of a joint venture with Axcelead, Inc., and is currently building a production plant in Minamisoma City, Fukushima Prefecture. In the upcoming years, such investments are probably going to supplement market expansion.

Advantages of mRNA Vaccines

mRNA vaccine production has advantages over the other counterparts, when compared to the production of most vaccines, since it does not require the use of cell cultures. The risk of contamination is smaller than what is seen with other sophisticated vaccine manufacturing techniques because of its quick reaction time. Additionally, mRNA vaccines are safer due to their non-integrative nature and transitory expression within cells. Using lipid-encapsulated or naked forms of sequence-optimized mRNA, mRNA vaccines have produced potent immunity against infectious disease targets in animal models of influenza virus, Zika virus, rabies virus, and others, particularly in recent years.

Increasing Research Activities to produce mRNA-based Vaccines

The numerous benefits mRNA offers over other therapeutic modalities, such as higher biological efficacy, enhanced potent immunogenicity, and versatile delivery platforms at low toxicity levels, are the main drivers of the ongoing research and development efforts being made in this field. The development of mRNA-based vaccines to prevent infectious or chronic diseases like diabetes, HIV, cancer, and cardiovascular diseases is the subject of extensive research. There are currently 430 clinical trials using mRNA vaccines to prevent diseases other than COVID-19. The majority of these clinical trials, according to an analysis by Clinicaltrials.gov, are conducted in the United States.

A multivalent, mRNA-based vaccine that protects against all 20 known influenza virus subtypes has been created by researchers at the Perelman School of Medicine at the University of Pennsylvania. They take a different approach from earlier attempts to create a universal flu vaccine by including antigens unique to each subtype rather than just a smaller set of antigens shared by subtypes. The SARS-CoV-2 vaccines made by Pfizer and Moderna used the same mRNA technology as this strategy. Penn was a leader in the development of the mRNA technology used in those COVID-19 vaccines.

Market Segmentation

Global mRNA Vaccine Market can be segmented by mRNA type, by application, and by region. Based on mRNA type, the market can be divided into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA. Based on application the market is divided into COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, and others. Regionally, the mRNA Vaccine can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company Limited., Ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, Verve Therapeutics Inc., are some of the leading players operating in the Global mRNA Vaccine Market.

Report Scope

In this report, Global mRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Global mRNA Vaccine Market, By mRNA Type:

  • Nucleoside-modified mRNA
  • Unmodified mRNA
  • Self-Amplifying mRNA

Global mRNA Vaccine Market, By Application:

  • COVID-19 mRNA Vaccines
  • Non COVID-19 mRNA Vaccines
  • Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global mRNA Vaccine Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

  • 4.1. Ongoing Clinical Trials
  • 4.2. Completed Clinical Trials
  • 4.3. Terminated Clinical Trials
  • 4.4. Breakdown of Pipeline, By Development Phase
  • 4.5. Breakdown of Pipeline, By Status
  • 4.6. Breakdown of Pipeline, By Study Type
  • 4.7. Breakdown of Pipeline, By Region
  • 4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global mRNA Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.4. By Company (2022)
  • 6.3. Product Map
    • 6.3.1. By mRNA Type
    • 6.3.2. By Application
    • 6.3.3. By Region

7. North America mRNA Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States mRNA Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By mRNA Type
        • 7.3.1.2.2. By Application
    • 7.3.2. Canada mRNA Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By mRNA Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Mexico mRNA Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By mRNA Type
        • 7.3.3.2.2. By Application

8. Europe mRNA Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France mRNA Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By mRNA Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany mRNA Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By mRNA Type
        • 8.3.2.2.2. By Application
    • 8.3.3. United Kingdom mRNA Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By mRNA Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy mRNA Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By mRNA Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Spain mRNA Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By mRNA Type
        • 8.3.5.2.2. By Application

9. Asia-Pacific mRNA Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China mRNA Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By mRNA Type
        • 9.3.1.2.2. By Application
    • 9.3.2. India mRNA Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By mRNA Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Japan mRNA Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By mRNA Type
        • 9.3.3.2.2. By Application
    • 9.3.4. South Korea mRNA Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By mRNA Type
        • 9.3.4.2.2. By Application
    • 9.3.5. Australia mRNA Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By mRNA Type
        • 9.3.5.2.2. By Application

10. South America mRNA Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil mRNA Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By mRNA Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina mRNA Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By mRNA Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia mRNA Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By mRNA Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa mRNA Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
    • 11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa mRNA Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By mRNA Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By mRNA Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE mRNA Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By mRNA Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Merger Acquisition
  • 13.3. Product launches

14. Global mRNA Vaccine Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
    • 16.6.1. Arcturus Therapeutics Holdings Inc.
    • 16.6.2. BioNTech SE
    • 16.6.3. CureVac N.V.
    • 16.6.4. Daiichi Sankyo Company Limited.
    • 16.6.5. Ethris GmbH
    • 16.6.6. GlaxoSmithKline plc
    • 16.6.7. Gennova Biopharmaceuticals Ltd
    • 16.6.8. Moderna, Inc.
    • 16.6.9. Pantherna Therapeutics GmbH
    • 16.6.10. Providence Therapeutics
    • 16.6.11. Silence Therapeutics
    • 16.6.12. Translate Bio
    • 16.6.13. VERSAMEB AG
    • 16.6.14. Verve Therapeutics Inc.

17. Strategic Recommendations